Understanding broad MPXV and Smallpox vaccination-derived immunity in regards to immunodominant antigens.

Developing serological assays to assess immunity, as well as performing MPXV-specific serosurveillance and determining vaccine-prioritisation.

Using the knowledge gained from understanding Mpox immunology and assay development, we have applied this to develop a low-cost and accurate MPXV-specific antibody lateral flow test.

Determining the risk of H5N1 spillover in at-risk areas at a population-level using national blood donor samples.

Utilising next-generation molecular methods and sequencing to enable epitope-level identification of antibody:antigen interactions.